The objectives were to characterize the impact of DM on COVID-19-related outcomes in relation to inflammation, identify key risk factors among patients with DM, and explore the interactions between inflammatory biomarkers, hyperglycemia, insulin therapy, and in-hospital outcomes. The gene discussed is INS; the disease is diabetes mellitus.